Importantly, we showed in a panel of clinically relevant patient‐derived avatars of HCC that the concurrent attenuation of the two vulnerabilities of c‐Myc, G9a and CDK9, was synergistic, reflecting the clinical relevance of this treatment strategy against Myc‐addicted HCC. The gene discussed is EHMT2; the disease is hepatocellular carcinoma.